Skip to main content
. 2018 Aug 17;9(4):224–233. doi: 10.1007/s13340-018-0368-9

Fig. 6.

Fig. 6

Overproduction of hepatokines contributes to the various kinds of pathologies observed in type 2 diabetes and obesity. Our studies open the door for inhibitor of hepatokine production as novel drugs for type 2 diabetes-associated pathologies. LECT2 leukocyte cell-derived chemotaxin 2, LRP1 low-density lipoprotein receptor-related protein 1, WAT white adipose tissue